Figure S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

<p>Kaplan Meier plots depict the association between PSMA+ CTC enumeration and OS and PFS. The associations of PSMA+ CTC enumeration with overall survival (OS) and progression-free survival (PFS) were explored using the proportional hazard model. A) The median OS in months for CTC=0 (reference), CTC+ PSMA-CTC, CTC+ PSMA+CTC but heterogeneous (<100%), and CTC+ PSMA+ 100% (homogeneous), respectively, were 25.7 (95% CI=19.8-NR), 24.5 (95% CI=16.7-30.4),15.6 (95% CI=14.4-20.7), and 35.0 (95% CI=16.9-NA). Univariate hazard ratio (HR) was 1.3 (95% CI=0.7-2.6), 2.0 (95% CI=1.0-3.8) and 0.7; 95% CI = 0.2-2.1 for CTC+, PSMA-CTC, CTC+ PSMA CTC+ but heterogeneous (<100%), and CTC+ PSMA+ 100% (homogeneous) vs. CTC=0, respectively. B) The median PFS for CTC=0 (reference), CTC+, PSMA-CTC, CTC+ PSMA+ CTC but heterogeneous (<100%), and CTC+ PSMA+ 100%, respectively, were 7.6 (95% CI=6.7-16.5), 6.0 (95% CI=3.5-11.4),5.5 (95% CI=3.6-7.6), and 5.7 (95% CI=3.0-NA). Univariate HR was 1.4 (95% CI=0.8-2.6), 2.0 (95% CI=1.1-3.6) and 1.5; 95% CI = 0.7-3.6 for CTC+, PSMA-CTC, CTC+ PSMA+ CTC but heterogeneous (<100%), and CTC+ PSMA+ 100% (homogeneous) vs. CTC=0, respectively.</p>

Duke Scholars

Author Daniel James George Medicine, Medical Oncology

Author Andrew John Armstrong Medicine, Medical Oncology

Author Susan Halabi Biostatistics & Bioinformatics, Division of Biostatistics